- |||||||||| IMM47 / ImmuneOnco Biopharma
Preclinical development of a monoclonal antibody targeting CD24 as cancer immunotherapy (Section 22; Poster Board #16) - Mar 14, 2023 - Abstract #AACR2023AACR_8525; Our data has also confirmed that IMM47 specifically binds to and induces ADCC (antibody-dependent cellular cytotoxicity) ,ADCP (antibody-dependent cellular phagocytosis), and CDC (complement-dependent cytotoxicity) against a variety of cancer cells. Taken together, our data show that targeting CD24 on tumor cells using our IMM47 antibody may serve as potent immunotherapy for multiple cancer indications.
|